We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Advanced Prostate Cancer
Center of Excellence
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Prostate Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Prostate Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No comments yet, be the first to start the discussion!
mohamed lemine sow
May 26, 2022
AS a radiologique biologique progression ECOG1,i will start abiraterone acetate plus prednisone
Ismail Abdelhafeez
May 26, 2022
Start Docetaxel
deepak dabkara
May 26, 2022
I will opt for docetaxel. 15 months response to Adt and enzalutamide can not be considered a very good response. Patient has psa and radiological progression. Very unlikely that he will respond to AA- Pred
deepak dabkara
May 26, 2022
I will opt for docetaxel. 15 months response to Adt and enzalutamide can not be considered a very good response. Patient has psa and radiological progression. Very unlikely that he will respond to AA- Pred
Eman Ahmed
May 26, 2022
2. Remaining on enzalutamide and add Radium223
Juan Artigas
May 26, 2022
Remain in enzalutamide and add Docetaxel
Charles Maack
May 26, 2022
start docetaxel 75 mg/m2
leo badinez
May 29, 2022
sbrt and evaluate psa response
HUGO OTAOLA ARCA
May 29, 2022
Start docetaxel
Manuel Ossa
May 31, 2022
Starts Docetaxel
Vladimira Stahalova
Jun 29, 2022
start docetaxel 75 mg/m2
Nov 17, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
mohamed lemine sow
May 26, 2022
Ismail Abdelhafeez
May 26, 2022
deepak dabkara
May 26, 2022
deepak dabkara
May 26, 2022
Eman Ahmed
May 26, 2022
Juan Artigas
May 26, 2022
Charles Maack
May 26, 2022
leo badinez
May 29, 2022
HUGO OTAOLA ARCA
May 29, 2022
Manuel Ossa
May 31, 2022
Vladimira Stahalova
Jun 29, 2022
Nov 17, 2024
Pending Moderator approval.